| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/14/2002 | WO2002012435A1 Method of producing infectious reovirus |
| 02/14/2002 | WO2002012347A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | WO2002012346A2 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | WO2002012341A2 Her-2/neu fusion proteins |
| 02/14/2002 | WO2002012340A2 Transporters and ion channels |
| 02/14/2002 | WO2002012339A2 Sequences for integrin alpha-8 |
| 02/14/2002 | WO2002012329A2 Compositions and methods for the therapy and diagnosis of head and neck cancer |
| 02/14/2002 | WO2002012326A2 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | WO2002012324A1 A new polypeptide-human l1 factor orf2 reverse transcription-related protein 13 and the polynucleotide encoding it |
| 02/14/2002 | WO2002012323A1 A new polypeptide- hlyd protein family secretory protein 11 and the polynucleotide encoding it |
| 02/14/2002 | WO2002012322A1 A new polypeptide-human fk506 binding protein 12.32 and the polynucleotide encoding it |
| 02/14/2002 | WO2002012309A1 A new polypeptide- phytochrome 9.9 and the polynucleotide encoding it |
| 02/14/2002 | WO2002012308A1 A new polypeptide-human rs3 protein 18 and the polynucleotide encoding it |
| 02/14/2002 | WO2002012306A1 A novel polypeptide-the human non-integrin metalloprotease 10.67 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012305A1 A novel-polypeptide-the avidin 9 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012304A1 A novel polypeptide-mouse transient receptor potential protein 2 (trp2)12 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012303A1 A novel polypeptide-human ribonucleoside dephosphate reductase inhibitor 10.23 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012302A1 A novel polypeptide-the human splicing factor 9.24 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012301A1 A novel polypeptide-insulin-like growth factor binding protein 16.17 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012300A1 A novel polypeptide-human cyclin g29.13 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012298A1 A novel polypeptide --the human nadh dehydrogenase subunit i-9 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012297A1 A novel polypeptide- human tropodulin 9 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012296A1 A novel polypeptide-nadp dependent leukotriene b412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002012286A2 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | WO2002012281A2 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| 02/14/2002 | WO2002012280A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 02/14/2002 | WO2002012272A2 Therapeutic anti-melanoma compounds |
| 02/14/2002 | WO2002012258A1 New immunoeffector compounds |
| 02/14/2002 | WO2002012250A2 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 02/14/2002 | WO2002012245A2 Azabicyclic derivatives and their therapeutic use |
| 02/14/2002 | WO2002012242A2 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/14/2002 | WO2002012240A1 Derivatives of variolin b |
| 02/14/2002 | WO2002012239A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | WO2002012238A2 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| 02/14/2002 | WO2002012235A1 1,4-dihydropyridines as bradykinin antagonists |
| 02/14/2002 | WO2002012228A1 Cinnoline compounds |
| 02/14/2002 | WO2002012227A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012226A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012225A1 Salts of benzimidazole compound and use thereof |
| 02/14/2002 | WO2002012223A2 Synthetic salicylihalamides, apicularens and derivatives thereof |
| 02/14/2002 | WO2002012210A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | WO2002012196A2 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | WO2002012194A1 Phenantridine derivatives and their use as anti-telomerase agent |
| 02/14/2002 | WO2002012193A1 Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| 02/14/2002 | WO2002012188A2 Indole compounds useful for the treatment of cancer |
| 02/14/2002 | WO2002012181A1 Novel diamines having a casr modulating activity |
| 02/14/2002 | WO2002012168A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | WO2002011772A2 Radiolabelled metal transport proteins as imaging agents |
| 02/14/2002 | WO2002011769A1 Vascular endothelial growth factor 2 |
| 02/14/2002 | WO2002011762A2 Methods and compositions for modulating tumor growth |
| 02/14/2002 | WO2002011759A1 Vaccines against cytokines and growth factors derived from malignant tumours |
| 02/14/2002 | WO2002011747A2 Transglutaminase for inhibiting angiogenesis |
| 02/14/2002 | WO2002011743A2 Treatment of prostate cancer |
| 02/14/2002 | WO2002011742A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/14/2002 | WO2002011740A2 'slow release' pharmaceutical compositions comprising lithium carbonate |
| 02/14/2002 | WO2002011730A1 Radiosensitising agent for curing oncological diseases |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | WO2002011705A2 Composition for combined use of aromatase inhibitors |
| 02/14/2002 | WO2002011704A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | WO2002011668A2 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients |
| 02/14/2002 | WO2002011667A2 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 02/14/2002 | WO2002011666A2 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 02/14/2002 | WO2002011563A1 Food supplement |
| 02/14/2002 | WO2002011530A1 Transgenic animal |
| 02/14/2002 | WO2002011513A1 A novel polypeptide-human ehd protein 9.57 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002011512A1 Novel polypeptide--the human mitochonrial cadherin 10.12 and polynucleotide encoding it |
| 02/14/2002 | WO2002011511A1 A novel polypeptide-the activating gtpase negative regulator 11.66 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2002011510A1 A novel polypeptide-human l1 motif-like orf2 protein 21 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001075073A3 Prostate cell lines and their use |
| 02/14/2002 | WO2001073018A3 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 02/14/2002 | WO2001072328A3 Methods of treating diseases with activated protein c |
| 02/14/2002 | WO2001070766A3 Therapeutic anti-cytomegalovirus compounds |
| 02/14/2002 | WO2001068663B1 Nucleoside compounds and uses thereof |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058922A3 Method and compositions for treating hepatocellular cancer |
| 02/14/2002 | WO2001058921A3 Methods and compositions for generating angiostatin |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001056598A3 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 02/14/2002 | WO2001055119A3 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2002 | WO2001055092A3 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 02/14/2002 | WO2001051619A3 Genetically modified fibroblast cell |
| 02/14/2002 | WO2001049705A3 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 02/14/2002 | WO2001049274A3 Methods for pulmonary delivery of interleukin-2 |
| 02/14/2002 | WO2001048161A3 Human heparanase-related polypeptide and nucleic acid |
| 02/14/2002 | WO2001044489A3 Galactomannan oligosaccharides and methods for the production and use thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001034137A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2001012169A3 Method of cancer treatment |
| 02/14/2002 | WO2000067698A3 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation |
| 02/14/2002 | WO2000064431A9 Pharmaceutical compositions of tetrac and methods of use thereof |
| 02/14/2002 | WO2000044908A9 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | WO1995029669A3 Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019538 Prevention binding of transcription factor tozinc finger binding compounds |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |